Immutep reports 81.1% 12-month disease-free survival in Phase II sarcoma trial

IMMP•2026-11-10

Immutep reported 81.1% 12-month disease-free survival in its Phase II EFTISARC-NEO trial in resectable soft tissue sarcoma. The trial evaluates eftilagimod alfa with Keytruda and radiotherapy before surgery.

1. Survival results

Immutep released preliminary survival results from its Phase II EFTISARC-NEO trial, reporting 81.1% 12-month disease-free survival in patients with resectable soft tissue sarcoma. Investigators said the findings warrant trials aimed at supporting registration; follow-up is ongoing.

Sources

Immutep reports 81.1% 12-month disease-free survival in Phase II sarcoma trial

Publicnow

Immutep reports 81.1% 12-month disease-free survival in Phase II sarcoma trial

1. Survival results

Related News

Snowflake director Michael L. Speiser reports $13.77 million common share disposal

Our Bond enters amended and restated leak-out agreement on Nov. 10, 2026

Atara Biotherapeutics prospectus covers up to $200 million in securities

Sources

Immutep reports 81.1% 12-month disease-free survival in Phase II sarcoma trial

Fox Corporation files pricing term sheet for $8.35 billion of senior notes in seven tranches

Blackstone Infrastructure announces acquisition of Portland Natural Gas Transmission System